Trial Profile
Temsirolimus for the Treatment of Advanced Hepatocellular Carcinoma in Patients With Intolerance to Sorafenib
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 16 Apr 2011 New trial record